SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500ng/mL, approximately 50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p<0.0001). This large dataset prospectively confirms the efficacy and well characterizes the safety profile of deferasirox in MDS.

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.

Gattermann N.;Finelli C.;Porta M. D.;Fenaux P.;Ganser A.;Guerci Bresler A.;Schmid M.;Taylor K.;Vassilieff D.;Habr D.;Domokos G.;Roubert B.;Rose C.;Agaoglu L.;Alimena G.;Alonso D.;Ame S.;Angelucci E.;Businco A.;Arrizabalaga B.;Athanasiou Metaxa M.;Augustson B.;Aydinok Y.;Baba A.;Baccarani M.;Beck J.;Beris P.;Beyne Rauzy O.;Birgens H.;Bordessoule D.;BORGNA, Caterina;Bosly A.;Bouabdallah K.;Bowden D.;Bowen D.;Bron D.;Cappellini M. D.;Capra M.;Cartron G.;Cazzola M.;Chalkias C.;Chan L. L.;Chancharunee S.;Chapman C.;Charoenkwan P.;Chasapopoulou E.;Cheze S.;Chuansumrit A.;Cianciulli P.;Dauriac C.;Delforge M.;Dölken G.;Dombret H.;Duyster J.;Economopoulos T.;Ehninger G.;Elalfy M.;El Beshlawy A.;Enggaard L.;Fillet G.;Filosa A.;Forni G.;Galanello R.;Gastl G.;Giraudier S.;Goldfarb A.;Grigg A.;Gumruk F.;Ha S. Y.;Haase D.;Heinrich B.;Hertzberg M.;Ho J.;Hsu H. C.;Huang S.;Hunault Berger M.;Inusa B.;Jaulmes D.;Jensen J.;Kattamis A.;Kilinc Y.;Kim K. H.;Kinsey S.;Kjeldsen L.;Koren A.;Lai M. E.;Lai Y.;Lee J. W.;Lee K. H.;Lee S. H.;Legros L.;Li C.;Li C. K.;Li Q.;Lin K. H.;Linkesch W.;Lübbert M.;Lutz D.;Mohamed Thalha A. J.;Mufti G.;Muus P.;Nobile F.;Papadopoulos N.;Perrotta S.;Petrini M.;Pfeilstöcker M.;Piga A.;Poole J.;Porter J. B.;Pungolino E.;Quarta G.;Ravoet C.;Jolimont Lobbes H. H.;Remacha A. F.;Roy L.;Saglio G.;Sanz G.;Schmugge M.;Schots H.;Secchi G.;Seymour J. F.;Shah F.;Shah H.;Shen Z.;Slama B.;Sutcharitchan P.;Taher A.;Tamary H.;Tesch H. J.;Thein S. L.;Troncy J.;Villegas A.;Viprakasit V.;Wainwright L.;Wassmann B.;Wettervald M.;Will A.;Wörmann B.;Wright J.;Yeh S. P.;Yoon S. S.;Zoumbos N. S.;Zweegman S.

2010

Abstract

The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500ng/mL, approximately 50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p<0.0001). This large dataset prospectively confirms the efficacy and well characterizes the safety profile of deferasirox in MDS.

Scheda breve

Scheda completa

Scheda completa (DC)

	Anno di pubblicazione
	
			2010
		
	DOI
	
			https://dx.doi.org/10.1016/j.leukres.2010.03.009
		
	Titolo della Rivista
	
			LEUKEMIA RESEARCH
		
	Tutti gli autori
	
			Gattermann, N.; Finelli, C.; Porta, M. D.; Fenaux, P.; Ganser, A.; Guerci Bresler, A.; Schmid, M.; Taylor, K.; Vassilieff, D.; Habr, D.; Domokos, G.; Roubert, B.; Rose, C.; Agaoglu, L.; Alimena, G.; Alonso, D.; Ame, S.; Angelucci, E.; Businco, A.; Arrizabalaga, B.; Athanasiou Metaxa, M.; Augustson, B.; Aydinok, Y.; Baba, A.; Baccarani, M.; Beck, J.; Beris, P.; Beyne Rauzy, O.; Birgens, H.; Bordessoule, D.; Borgna, Caterina; Bosly, A.; Bouabdallah, K.; Bowden, D.; Bowen, D.; Bron, D.; Cappellini, M. D.; Capra, M.; Cartron, G.; Cazzola, M.; Chalkias, C.; Chan, L. L.; Chancharunee, S.; Chapman, C.; Charoenkwan, P.; Chasapopoulou, E.; Cheze, S.; Chuansumrit, A.; Cianciulli, P.; Dauriac, C.; Delforge, M.; Dölken, G.; Dombret, H.; Duyster, J.; Economopoulos, T.; Ehninger, G.; Elalfy, M.; El Beshlawy, A.; Enggaard, L.; Fillet, G.; Filosa, A.; Forni, G.; Galanello, R.; Gastl, G.; Giraudier, S.; Goldfarb, A.; Grigg, A.; Gumruk, F.; Ha, S. Y.; Haase, D.; Heinrich, B.; Hertzberg, M.; Ho, J.; Hsu, H. C.; Huang, S.; Hunault Berger, M.; Inusa, B.; Jaulmes, D.; Jensen, J.; Kattamis, A.; Kilinc, Y.; Kim, K. H.; Kinsey, S.; Kjeldsen, L.; Koren, A.; Lai, M. E.; Lai, Y.; Lee, J. W.; Lee, K. H.; Lee, S. H.; Legros, L.; Li, C.; Li, C. K.; Li, Q.; Lin, K. H.; Linkesch, W.; Lübbert, M.; Lutz, D.; Mohamed Thalha, A. J.; Mufti, G.; Muus, P.; Nobile, F.; Papadopoulos, N.; Perrotta, S.; Petrini, M.; Pfeilstöcker, M.; Piga, A.; Poole, J.; Porter, J. B.; Pungolino, E.; Quarta, G.; Ravoet, C.; Jolimont Lobbes, H. H.; Remacha, A. F.; Roy, L.; Saglio, G.; Sanz, G.; Schmugge, M.; Schots, H.; Secchi, G.; Seymour, J. F.; Shah, F.; Shah, H.; Shen, Z.; Slama, B.; Sutcharitchan, P.; Taher, A.; Tamary, H.; Tesch, H. J.; Thein, S. L.; Troncy, J.; Villegas, A.; Viprakasit, V.; Wainwright, L.; Wassmann, B.; Wettervald, M.; Will, A.; Wörmann, B.; Wright, J.; Yeh, S. P.; Yoon, S. S.; Zoumbos, N. S.; Zweegman, S.
		
	Appare nelle tipologie:
	
			03.1 Articolo su rivista

File in questo prodotto:

Non ci sono file associati a questo prodotto.

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/1402568

Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni

ND

161

148

social impact